microdose glp 1 menopause GLP-1 Microdosing During Menopause: Is it Right for You? What Is Microdosing GLP-1s, and

For more information on how to download MyChart onto your mobile device, please contact our 24/7 Patient Help Desk at or email us at

In clinical trials, semaglutide (Wegovy) patients lost an average of ~15% of body weight over 68 weeks

Weight loss remains a central therapeutic driver: A reduction in body weight of at least 7 to 10 percent resolves NASH in approximately 65 to 90 percent of patients

Common GLP-1 Medications Available Semaglutide (Ozempic and Wegovy) - Semaglutide stands out for its notable results in both weight loss and blood sugar management

2 More detailed elucidation of the actions and benefits of GLP-1 medicines that might be partly independent of weight loss and glucose metabolism may provide new therapeutic opportunities to precisely target and further expand the use of GLP-1 therapeutics, perhaps, where weight loss may not be paramount, using lower doses that are less costly and associated with fewer adverse events